A consolidated subsidiary of ADRバイオメディカルホールディングス has entered into a joint research agreement with Nagoya University and will begin experiments to evaluate NeoCella's mechanism of action in human endometrial cells and changes in the expression of implantation-related genes and proteins. The study is expected to run from 25 September 2026 to 24 September 2027.
ADRバイオメディカルホールディングス announced that it has entered into a joint research agreement with Nagoya University and will conduct research aimed at analyzing NeoCella's functional properties. The study will use human endometrial cells to evaluate changes in the expression of implantation-related genes and proteins.
In the joint research, NeoCella, including extracellular particles, will be added to human endometrial cells to observe changes in implantation-related expression, and molecules associated with its mechanism of action will also be analyzed. The study is scheduled to run from 25 September 2026 to 24 September 2027, after which the potential for the next stage of research and development and commercialization will be considered based on the results.